6500 Hollister Avenue
105 articles with Sientra, Inc.
Eight Breast Cancer Nonprofits across the U.S. Selected to Receive Funding
Program supports breast cancer and reconstruction research and education
Sientra Reports the Long-term Safety and Effectiveness of Silicone Gel Breast Implants with Results from the Largest Core Breast Implant Trial To-Date
The four-part supplement, which includes the Company's finalized 10-year FDA Core Study, provides a comprehensive look at the long-term outcomes, surgical best practices and product differentiation of Sientra's breast implants and tissue expanders.
Sientra Launches New miraDry fresh Protocol for the miraDry® System at American Academy of Dermatology Annual Meeting
The miraDry treatment is the first and only FDA-cleared solution to permanently reduce underarm sweat, odor and hair of all colors with as little as one treatment, in one hour with immediate results.
The Company believes that the information requested by the FDA related to this third and final outstanding submission can be addressed quickly and is working closely with the FDA to resolve these matters in a timely manner.
The new employees were granted restricted stock units representing a total of 257,235 shares of common stock.
In addition, the Company appointed Keith Sullivan as interim General Manager of miraDry, a Sientra subsidiary.
Total net sales for the third quarter 2017 were $9.8 million, compared to total net sales of $6.5 million for the same period in 2016.
Sientra will hold a conference call on Tuesday, November 7, 2017 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
Industry Leaders Allergan And Sientra Invest In The American Society For Aesthetic Plastic Surgery For Breast Implant Research
Sientra To Release Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, August 9, 2017
Ongoing Safety And Efficacy Of Sientra Silicone Gel Breast Implants Supported By Nine Years Of Follow-Up Data